BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15942701)

  • 1. Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones.
    Kawamura-Sato K; Hasegawa T; Torii K; Ito H; Ohta M
    Curr Microbiol; 2005 Jul; 51(1):27-30. PubMed ID: 15942701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.
    Ip M; Chau SS; Chi F; Qi A; Lai RW
    J Clin Microbiol; 2006 Mar; 44(3):970-5. PubMed ID: 16517885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
    Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
    Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Korzheva N; Davies TA; Goldschmidt R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.
    Patel SN; Melano R; McGeer A; Green K; Low DE
    Ann Clin Microbiol Antimicrob; 2010 Jan; 9():3. PubMed ID: 20082699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
    Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
    Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substitutions of Ser83Leu in GyrA and Ser80Leu in ParC Associated with Quinolone Resistance in Acinetobacter pittii.
    Gu DX; Hu YJ; Zhou HW; Zhang R; Chen GX
    Microb Drug Resist; 2015 Jun; 21(3):345-51. PubMed ID: 25514581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
    Zhang FF; Zhao CJ; Wang H
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
    Weigel LM; Anderson GJ; Facklam RR; Tenover FC
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.
    Balsalobre L; de la Campa AG
    Antimicrob Agents Chemother; 2008 Mar; 52(3):822-30. PubMed ID: 18160515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.
    Stewart BA; Johnson AP; Woodford N
    J Med Microbiol; 1999 Dec; 48(12):1103-1106. PubMed ID: 10591164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
    Canton R; Morosini M; Enright MC; Morrissey I
    J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae from Asian countries: ANSORP study.
    Oh WS; Suh JY; Song JH; Ko KS; Jung SI; Peck KR; Lee NY; Yang Y; Chongthaleong A; Chiu CH; Kamarulzaman A; Parasakthi N; Lalitha MK; Perera J; Yee TT; Kumarasinghe G; Carlos CC;
    Microb Drug Resist; 2004; 10(1):37-42. PubMed ID: 15140392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent topoisomerase IV mutations associated with fluoroquinolone resistance in Ureaplasma species.
    Song J; Qiao Y; Kong Y; Ruan Z; Huang J; Song T; Zhang J; Xie X
    J Med Microbiol; 2015 Nov; 64(11):1315-1320. PubMed ID: 26243148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.